NU Sinersen / Spinraza Guideline

Medical Necessity
Gold Coast Health Plan (GCHP) considers nusinersen (Spinraza) medically necessary for persons with spinal muscular atrophy (SMA) who meet all of the following criteria:

A. Member has SMA types I, II or III based on genetic testing;
AND
B. There is genetic documentation of 5q SMA homozygous gene mutation, homozygous gene deletion, or compound heterozygote;
AND
C. The medication is prescribed by or in consultation with a physician who specializes in treatment of spinal muscular atrophy.

Continued Use of Nusinersen
Continued use of nusinersen is considered medically necessary for members who have responded to therapy, as demonstrated by maintenance or improvement in motor milestones.

Experimental / investigational and not medically necessary
GCHP considers nusinersen experimental and investigational for all other indications.

Dosage
The medically-necessary dosage of nusinersen is 12 mg (5 mL) per administration. Four loading doses of nusinersen are considered medically necessary for initiation of treatment. The first three loading doses are administered at 14-day intervals; the fourth loading dose is administered 30 days after the third dose. A maintenance dose is considered medically necessary once every four months thereafter.

References


Medical Advisory Committee Guideline History

<table>
<thead>
<tr>
<th>Adopted By MAC</th>
<th>Reapproved</th>
<th>Revised</th>
<th>Retired</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 25, 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 25, 2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 23, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 21, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>